Other substances

Cobicistat

A cytochrome P450 3A inhibitor.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Cobicistat is a cytochrome P450 3A inhibitor which is used as a pharmacokinetic enhancer for certain HIV-1 antivirals (NCIt).

Cobicistat on DrugBank
Cobicistat on PubChem
Cobicistat on Wikipedia

CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial Small molecule Randomized controlled open trial	Patients	3.62	darunavir/cobicistat (800mg/150mg, qd, po.) in combination with interferon alpha inhalation (100,000 iu, tid or qid)	Oct/25/2020
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19 Preprint Screening	human A549-ACE2 cells			Jun/23/2020
Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection Small molecule Critical severity Cohort study	Patients	1.78	Used as an adjuvant for Darunavir in a fixed-dose. Significant increase in survival in critically ill patients. Sample size: 14 + 28 control. Dosage: 150 mg.	Aug/27/2020
Structure-Based Virtual Screening and Biochemical Validation to Discover a Potential Inhibitor of the SARS-CoV-2 Main Protease 3CLpro Biophysical assay Small molecule Enzyme assay In vitro In silico	in silico; in vitro enzyme assay; in vitro biophysical assay	2.87	The compound inhibited the SARS-CoV-2 3C-like protease in vitro with IC50 of ca. 6.7 μM and the corresponding KD was calculated to be ca. 2.1 μM.	Dec/17/2020

AI-suggested references

Link	Publication date
Whole genome analysis and homology modeling of SARS-CoV-2 Indian isolate reveals potent FDA approved drug choice for treating COVID-19.	Apr/01/2022
Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia.	Jan/21/2022
Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.	Oct/13/2020
In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors	Jul/20/2020
The Use of Antiviral Agents against SARS-CoV-2: Ineffective or Time and Age Dependent Result? A Retrospective, Observational Study among COVID-19 Older Adults	Feb/10/2021
Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2	May/20/2020
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19	Mar/04/2021
The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus.	Jan/30/2021
Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19	Jun/21/2020
Data on the stability of darunavir/cobicistat suspension after tablet manipulation	Apr/12/2020
Peptide-like and small-molecule inhibitors against Covid-19	Sep/18/2021
Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2	Aug/03/2020
Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment.	Mar/22/2021
Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study	May/04/2022
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters	Mar/01/2022
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study	Jun/25/2021
Lack of antiviral activity of darunavir against SARS-CoV-2	Feb/03/2022

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04425382	Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar	Recruiting		Mar/01/2020	Sep/01/2020
Alternative id - MRC-05-069 Interventions - Drug: Darunavir/Cobicistat\|Drug: Lopinavir/Ritonavir Study type - Observational Study results - No Results Available Locations - Hamad Medical Corporation, Doha, Qatar Study designs - Observational Model: Other\|Time Perspective: Retrospective Enrollment - 200 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to Clinical Improvement and/or Virological Clearance (Composite Endpoint)\|Percentage of Virological Clearance\|Percentage of Clinical Deterioration\|Incidence of Adverse Events\|Length of Hospital Stay\|All-cause Mortality
NCT04252274	Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19	Recruiting	Phase 3	Jan/30/2020	Dec/31/2020
Alternative id - DC-COVID-19 Interventions - Drug: Darunavir and Cobicistat Study type - Interventional Study results - No Results Available Locations - Shanghai Public Health Clinical Center, Shanghai, Shanghai, China\|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 30 Age - Child, Adult, Older Adult Outcome measures - The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7\|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3\|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5\|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0\|The critical illness rate of subjects at weeks 2\|The mortality rate of subjects at weeks 2

Export (.csv)